Or it could be Block trade
Major broker-dealers often provide “block trading” services—sometimes known as “upstairs trading desks”—to their institutional clients. A block trade is a permissible, noncompetitive, privately negotiated transaction either at or exceeding an exchange determined minimum threshold quantity of shares, which is executed apart and away from the open outcry or electronic markets. In the United States and Canada a block trade is usually at least 10,000 shares of a stock or $100,000 of bonds but in practice significantly larger.
you don't have to nickles to rub together let alone short 50k. no one posts on yahoo a 100k trade putzer.
Schmuck I reposted something that I thought was new news. I mistook it and realized and admitted the mistake. So no I didn't pump.
05-Oct-2015:11:52:00, Novavax announces positive data from Phase I respiratory syncytial virus trial
Novavax, Inc., a clinical-stage biopharmaceutical company, has announced positive data from a Phase I clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate, or RSV F Vaccine, for respiratory syncytial virus, or RSV infection.
The trial was a randomized, observer-blinded, Phase I study to evaluate the safety and immunogenicity of the RSV F Vaccine, with one or two doses, with or without aluminum phosphate adjuvant, in healthy pediatric participants two to six years of age. The trials primary goal was to evaluate safety in this population and immunogenicity as measured by concentrations of serum IgG antibodies to the RSV fusion, or F-protein, palivizumab-competing antibody (PCA) titers and RSV microneutralization titers. Novavax concluded this trials enrollment with a smaller than planned cohort so dosing could be completed ahead of the 2014-2015 RSV season.
Of the 32 total children enrolled, serum samples were collected from a subset of 18 children in the per-protocol population at 14, 28 and 56 days. All RSV F Vaccine formulations and regimens were well-tolerated and highly immunogenic. Consistent with prior trials, anti-F IgG and PCA titers increased rapidly at day 14, peaked at day 28 and remained at elevated levels through day 56; the last time point currently analyzed. There were greater than 10-fold increases in both anti-F IgG and PCA antibody titers in the adjuvanted group and greater than 6-fold increases in anti-F IgG and PCA antibody titers in the unadjuvanted group.
"Given the seasonality of RSV and the fact that infection could confound interpretation of the data, we closed out the trial prior to the initiation of the RSV season. Despite the small population, we were able to observe that the vaccine has the potential to be both safe and immunogenic in young children," said Gregory Glenn, M.D., Senior vice president, R&D. "The strength of these data clearly support advancing the RSV vaccine into a Phase II pediatric trial."
"Our RSV F Vaccine has now elicited a robust immune response in all three of our target populations: older adults, infants via maternal immunization and pediatrics. We are evaluating this data in the context of our RSV F Vaccine overall clinical development program and look forward to providing an update in the next several months on our path forward in the pediatric population," said Stanley C. Erck, President and CEO.
"It should not be lost on those interested in Novavax that this announcement is the fifth positive clinical trial readout provided during the third quarter of this year, a pivotal achievement for the Company made possible by the power of our recombinant nanoparticle platform technology and this dedicated and experienced team."
Sentiment: Strong Buy
He's an idiot. Other than getting funding from Barda,WHO, Gates etc... he killed the market cap. So let's just say we were at 13-15 right now NVAX could have done a secondary and raised more money to expedite the last trials and SAVE NEWBORN lives. He doesn't realize that he's screwing with children.
Sentiment: Strong Buy
And the askholes are posting.
16:06 EDT NVAX
theflyonthewallcom: Novavax's RSV F vaccine meets safety endpoints in Phase 1 clinical trial
Novavax announced positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate - RSV F Vaccine - in healthy children. The trial evaluated the safety and immunogenicity of the RSV F Vaccine, with one or two doses, with or without aluminum phosphate adjuvant, in healthy pediatric participants two to six years of age. All RSV F Vaccine formulations and regimens were well-tolerated and highly immunogenic. There were greater than 10-fold increases in both anti-F IgG and PCA antibody titers in the adjuvanted group and greater than 6-fold increases in anti-F IgG and PCA antibody titers in the unadjuvanted group